Teva Pharms Company Profile

✉ Email this page to a colleague

TEVA PHARMS has three hundred and twenty approved drugs.

There are three US patents protecting TEVA PHARMS drugs. There are forty-three tentative approvals on TEVA PHARMS drugs.

There are nineteen patent family members on TEVA PHARMS drugs in twelve countries and nine hundred and forty-three supplementary protection certificates in eighteen countries.

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Teva Pharms Usa	CARBOPLATIN	carboplatin	INJECTABLE;INTRAVENOUS	077139-004	Sep 21, 2005		DISCN	No	No		⤷ Subscribe				⤷ Subscribe
Teva Pharms Usa	SUNITINIB MALATE	sunitinib malate	CAPSULE;ORAL	213803-004	Nov 30, 2021	AB	RX	No	No		⤷ Subscribe				⤷ Subscribe
Teva Pharms Usa	PIOGLITAZONE HYDROCHLORIDE	pioglitazone hydrochloride	TABLET;ORAL	077210-002	Jan 10, 2014	AB	RX	No	No		⤷ Subscribe				⤷ Subscribe
Teva Pharms	PROCHLORPERAZINE MALEATE	prochlorperazine maleate	TABLET;ORAL	040120-002	Jul 11, 1996		DISCN	No	No		⤷ Subscribe				⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Teva Pharms Usa	COPAXONE	glatiramer acetate	FOR SOLUTION;SUBCUTANEOUS	020622-001	Dec 20, 1996	7,199,098	⤷ Subscribe
Teva Pharms Intl	AMRIX	cyclobenzaprine hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	021777-002	Feb 1, 2007	7,790,199	⤷ Subscribe
Teva Pharms Intl	SYNRIBO	omacetaxine mepesuccinate	POWDER;SUBCUTANEOUS	203585-001	Oct 26, 2012	RE45128	⤷ Subscribe
Teva Pharms Usa	COPAXONE	glatiramer acetate	INJECTABLE;SUBCUTANEOUS	020622-003	Jan 28, 2014	6,054,430	⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	for Injection	100 mcg/vial and 500 mcg/vial	➤ Subscribe	2015-04-14
➤ Subscribe	Extended-release Capsule	15 mg and 30 mg	➤ Subscribe	2008-08-11
➤ Subscribe	Delayed-release Tablets	20 mg	➤ Subscribe	2015-06-03
➤ Subscribe	Injection	40 mg/mL, 1 mL pre-filled syringe	➤ Subscribe	2014-02-26
➤ Subscribe	for Injection	200 mcg/vial	➤ Subscribe	2015-05-01
➤ Subscribe	for Injection	3.5 mg/vial	➤ Subscribe	2016-10-26
➤ Subscribe	Injection	40 mg/mL, 1 mL pre-filled syringe	➤ Subscribe	2014-01-29

Patent Number	Expiration Date
⤷ Subscribe	⤷ Subscribe

Subscribe to access the full database, or Subscribe
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2962690	132019000000096	Italy	⤷ Subscribe	PRODUCT NAME: APREMILAST(OTEZLA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/14/981, 20150116
1534390	C20100006 00032	Estonia	⤷ Subscribe	PRODUCT NAME: REVOLADE-ELTROMBOPAG; REG NO/DATE: C(2010)1662 11.03.2010
1638574	6/2018	Austria	⤷ Subscribe	PRODUCT NAME: MIDOSTAURIN ODER EIN SALZ DAVON; REGISTRATION NO/DATE: EU/1/17/1218 20170920
1638574	CR 2018 00001	Denmark	⤷ Subscribe	PRODUCT NAME: MIDOSTAURIN ELLER ET SALT DERAF; REG. NO/DATE: EU/1/17/1218 20170920
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.